Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Endocrine |
| Therapuetic Areas: | Endocrinology, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | May 2008 |
| End Date: | November 2014 |
| Contact: | Novartis Pharmaceuticals |
| Phone: | +1(862)778-8300 |
Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation
This study will evaluate the impact of investigator and patient education and educational
materials to foster calcium and vitamin D supplementation to mitigate the potential for
hypocalcemia post Reclast® administration in patients with Paget's disease of bone.
Inclusion Criteria:
- Written informed consent
- As per currently approved Reclast® Package Insert:
Exclusion Criteria:
- As per currently approved Reclast® Package Insert:
We found this trial at
16
sites
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials